MFDS concluded that GX-188E met the criteria for this designation after assessing the complete set of Phase II results from the clinical trial that was recently completed in
The post Genexine receives FTD for DNA vaccine to treat advanced cervical cancer appeared first on Pharmaceutical Business review.